Program Description

Overall Program Objectives/Discussion Topics

This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease together with practicing clinicians to improve the care of patients at high risk of cardiovascular, metabolic, and kidney diseases. At HiD, experts and clinicians explore the state-of-the-art clinical science of the Heart in Diabetes, with in-depth examinations of the latest evidence from clinical trials on lipid disorders, glucose abnormalities, congestive heart failure, atherosclerosis, vascular disease, kidney disease, coagulation abnormalities, arrhythmia, and related conditions to understand their implications on practice.

Upon completion of this meeting, participants should be able to:

  • Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia

  • Evaluate the relationship between diabetes, the heart, and the kidney- the cardiorenal syndrome

  • Evaluate the extent of vascular disease in diabetes and cardiometabolic conditions

  • Provide management recommendations of cardiovascular conditions, in DM and Obesity

  • Evaluate the impact on the clinical practice of new cardiovascular outcome trials in patients with diabetes

  • Discuss the role of incretins in the management of obesity, diabetes, and their complications

  • Compare and contrast changes in lipid management guidelines: ACC/AHA vs AACE

  • Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-RAs to reduce cardiovascular mortality in patients with T2D

  • Describe the mechanism of action of SGLT2 inhibitors, GLP1-RAs, and EPA in reducing adverse cardiovascular outcomes

  • Evaluate the extent of CVD and CKD in diabetes and obesity

  • Describe the role of PCSK9 in lipid elevations and impact on CVD addressing role in women

  • Explain the relationship between diabetes, obesity, and congestive heart failure- focus on HFpEF and potential management

  • Discuss the role of SGLT2 inhibitors in the management of diabetes and  obesity addressing their complications

  • Recognize the role of the liver, fatty liver disease, and NASH in the development of CVD in diabetes

  • Describe changes in the epidemiology of cardiovascular and kidney disease in people with diabetes and obesity

  • Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes

  • Evaluate the proper administration of anti-platelet and anti-coagulation agents in the management of the high-risk patient

  • Acquire tools to understand how new agents impact CVD in DM to be able to consider SGLT2i vs GLP1ra vs PCSK9i vs EPA in people with DM and established CV disease

 

Initiative/Goal
  • To develop a platform to address the clinical science of the Heart in Diabetes

  • To identify the implications of state-of-the-art clinical research on cardiovascular, liver, and kidney disease in diabetes

  • To further advance the discussion between Cardiologists, Endocrinologists, Nephrologists, Lipidologists, and other interested clinicians, while developing an ongoing interaction in the management and prevention of heart disease in diabetes and cardiometabolic conditions

Target Audience

Cardiologists, endocrinologists, nephrologists, diabetologists, lipidologists, internists, family clinicians, and other professionals who are interested in the Heart in Diabetes.

18372 Clark St.

Suite 212

Tarzana, CA 91356

info@tmioa.com

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter